Reactions 1680, p99 - 2 Dec 2017 ALK and KRAS mutations leading to acquired crizotinib resistance: 12 case reports In a study of 20 patients, 12 patients (eight women and four men) aged between 40–81 years were described, who developed anaplastic lymphoma kinase (ALK; n=5) and Kirsten rat sarcoma (KRAS; n=10) gene mutations leading to acquired crizotinib resistance [routes and dosages not stated]. The patients had a history of advanced ALK-positive non small cell lung cancer (NSCLC) and started receiving treatment with tyrosine kinase inhibitor (TKI), crizotinib. The patients experienced disease progression at different site like lymph node (n=3), brain (n=9), liver (n=2), lung (n=2) and pleura (n=2). Subsequent investigations revealed development of ALK and KRAS gene mutations which conferred the resistance. The patients started receiving treatment with chemotherapy (one patient), brigatinib (n=9) and ceritinib (one patient). The disease was stable in three of the 12 patients. Disease progression was observed in another three patients [not all outcomes stated]. Author comment: "To our knowledge, this is the first report to evaluate the acquired resistance to ALK-TKIs using cfDNA in a cohort of crizotinib-resistant NSCLC patients." Bordi P, et al. Detection of ALK and KRAS Mutations in Circulating Tumor DNA of Patients With Advanced ALK-Positive NSCLC With Disease Progression During Crizotinib Treatment. Clinical Lung Cancer 18: 692-697, No. 6, Nov 2017. Available from: URL: http://doi.org/10.1016/j.cllc.2017.04.013 - Italy 803284377 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680
Reactions Weekly – Springer Journals
Published: Dec 2, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera